Protara Therapeutics, Inc.
NASDAQ:TARABiotechnology
-$0.05 today
- Market cap
- $144.07M
- Beta
- 1.45
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.48
Volume 1.15M
Average 0.73M
TARA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Protara Therapeutics, Inc.NASDAQ: TARA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $1.36M rose 63.5% year over year, ahead of the +16.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 30.6% from the prior quarter. Over 3 fiscal years it compounded at -17.0% a year.
Context
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +63.5% holds above the trailing-twelve-month pace of +16.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 3.83M USD
- Year-over-year change
- -7.2%
- 4-year CAGR
- -22.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.83M | -7.2% |
| FY2024 | 2024-12-31 | 4.13M | -32.3% |
| FY2023 | 2023-12-31 | 6.09M | -8.9% |
| FY2022 | 2022-12-31 | 6.69M | -35.5% |
| FY2021 | 2021-12-31 | 10.36M | — |
Stock-Based Compensation vs competitors
How TARA compares with its peers on the latest reported figures
- TARA's LTM Mar 2026 stock-based compensation of $4.36M is the 8th largest of the 10 companies compared; the peer median is $10.08M.
- Its year-over-year change of +16.7% is the 2nd highest of 9, against a peer median of -27.1%.
- Over three fiscal years its annual growth of -17.0% compares with a peer median of -8.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.21M | — | — | — | |
| LTM Mar 2026 | $15.02M | -24.7% | -4.8% | 52.0% | |
| LTM Mar 2026 | $11.86M | +7.9% | +52.0% | 36.3% | |
| LTM Mar 2026 | $11.51M | -33.2% | -18.7% | 20.6% | |
| LTM Mar 2026 | $10.08M | -60.8% | -22.0% | 60.3% | |
| LTM Mar 2026 | $8.67M | -29.5% | -12.8% | 11.1% | |
| LTM Mar 2026 | $7.48M | -39.0% | -34.0% | 21.6% | |
| LTM Mar 2026 | $4.36M | +16.7% | -17.0% | — | |
| LTM Sep 2026 | $4.19M | +122.7% | +4.3% | — | |
| LTM Mar 2026 | $2.91M | -16.2% | +16.9% | 20.1% | |
| Peer median (excluding TARA) | $10.08M | -27.1% | -8.8% | 21.6% | |
Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Depreciation & Amortization | 117K | 248K | 341K | 332K | 362K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.36M | 6.69M | 6.09M | 4.13M | 3.83M |
| Change in Working Capital | 534K | 539K | (4.14M) | 4.01M | (2.94M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 40K | 631K | 848K | 1.38M | (873K) |
| Other Working Capital | 494K | (92K) | (4.99M) | 2.63M | (2.07M) |
| Other Non-Cash Items | 1.74M | 32.02M | 569K | 324K | (173K) |
| Operating Cash Flow | (34.5M) | (26.46M) | (37.56M) | (35.81M) | (56.37M) |
| Capital Expenditures | (596K) | (120K) | (45K) | (63K) | (94K) |
| Acquisitions (Net) | 97.6K | (15.07K) | 0 | 0 | 0 |
| Purchases of Investments | (124.75M) | (43.55M) | (12.19M) | (29.38M) | (204.63M) |
| Sales of Investments | 27.15M | 58.62M | 65.34M | 48.6M | 65.23M |
| Other Investing Activities | (97.6K) | 15.07K | 0 | 0 | 0 |
| Investing Cash Flow | (98.19M) | 14.95M | 53.11M | 19.16M | (139.49M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 136.01M | 82.9M |
| Common Stock Repurchased | (228K) | (90K) | (91K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 3.86M | (185K) |
| Financing Cash Flow | (228K) | (90K) | (91K) | 139.87M | 82.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (132.92M) | (11.6M) | 15.46M | 123.21M | (113.14M) |
| Free Cash Flow | (35.1M) | (26.58M) | (37.6M) | (35.87M) | (56.46M) |
Protara Therapeutics, Inc.
NASDAQ:TARA
Intrinsic Alpha fair value
Locked
Current Price
$2.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.